抗凝固薬の世界市場

◆英語タイトル:Anticoagulants Market (Route of Administration - Oral, Injectables; Drug Class - Factor XA Inhibitors (NOAC/DOAC), Heparins, Direct Thrombin Inhibitors, Vitamin K Antagonists; Indication - Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Atrial Fibrillation and Heart Attack; Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026
◆商品コード:TPM-C03017
◆発行会社(リサーチ会社):Transparency Market Research
◆発行日:2019年2月
◆ページ数:159
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD5,795 ⇒換算¥637,450見積依頼/購入/質問フォーム
Multi UserUSD8,795 ⇒換算¥967,450見積依頼/購入/質問フォーム
Global Site LicenseUSD11,795 ⇒換算¥1,297,450見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTransparency Market Research社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Transparency Market Research社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

Transparency Market Researchが調査・発行した当レポートは、抗凝固薬の世界市場について調べ、抗凝固薬の世界規模、市場動向、市場環境、投与経路別(経口、注射剤)分析、薬剤クラス別(第Xa因子阻害薬、ヘパリン、直接トロンビン阻害剤、ビタミンK拮抗薬)分析、適応症別(深部静脈血栓症(DVT)、肺塞栓症(PE)、心房細動・心不全)分析、流通経路別(院内薬局、小売薬局、オンライン薬局)分析、アメリカ市場規模、ヨーロッパ市場規模、アジア市場規模、日本市場規模、中国市場規模、関連企業情報などをまとめました。
・序文・調査範囲・調査手法
・エグゼクティブサマリー
・抗凝固薬の世界市場動向
・抗凝固薬の世界市場環境
・抗凝固薬の世界市場規模
・抗凝固薬の世界市場規模:投与経路別(経口、注射剤)
・抗凝固薬の世界市場規模:薬剤クラス別(第Xa因子阻害薬、ヘパリン、直接トロンビン阻害剤、ビタミンK拮抗薬)
・抗凝固薬の世界市場規模:適応症別(深部静脈血栓症(DVT)、肺塞栓症(PE)、心房細動・心不全)
・抗凝固薬の世界市場規模:流通経路別(院内薬局、小売薬局、オンライン薬局)
・抗凝固薬の世界市場:地域別市場規模・分析
・抗凝固薬の北米市場規模・予測
・抗凝固薬のアメリカ市場規模・予測
・抗凝固薬の中南米市場規模・予測
・抗凝固薬のヨーロッパ市場規模・予測
・抗凝固薬のアジア市場規模・予測
・抗凝固薬の日本市場規模・予測
・抗凝固薬の中国市場規模・予測
・抗凝固薬のインド市場規模・予測
・抗凝固薬の中東市場規模・予測
・抗凝固薬のアフリカ市場規模・予測
・競争状況・関連企業情報
【レポートの概要】

Anticoagulants Market – Overview

Anticoagulants prevent clot formation or enlargement of existing clots in the arteries or veins. Heparins, including unfractionated heparin (UFH) and low molecular weight heparin (LMWH); vitamin K antagonists, DTIs, and factor Xa inhibitors, are the various anticoagulants available in the market. These are used for indications such as heart attack, stroke, deep venous thrombosis (DVT), pulmonary embolism (PE), surgery, angina, dialysis, atrial fibrillation (AF), thrombocytopenia, and myocardial infarction.

This report analyzes the current and future prospects of the global anticoagulants market. The report comprises an elaborate executive summary, including a market snapshot that provides overall information of various segments and sub-segments. The research is a combination of primary and secondary researches. Detailed qualitative analysis of factors responsible for driving and restraining the market and opportunities has been provided in the overview section. Market revenue in terms of US$ Mn for the period between 2016 and 2026 along with the compound annual growth rate (CAGR %) from 2018 to 2026 are provided for all the segments, considering 2017 as the base year. Market related factors such as technological developments, product innovation, and expansion of infrastructural facilities by major & small major products, and historical year-on-year growth have been taken into consideration while estimating the market size. Growth rates for each segments of the global anticoagulants market have been determined after a thorough analysis of past trends, demographics, future trends, technological developments, product development life cycle, and regulatory requirements. These factors would help the players to take strategic decisions in order to strengthen their positions and expand their share in the global market.

Based on route of administration, the global anticoagulants market has been bifurcated into oral and injectables. In terms of drug class, the market has been classified into factor Xa inhibitors (NOAC/DOAC), heparins, direct thrombin inhibitors, and vitamin K antagonists. Based on indication, the global anticoagulants market has been categorized into deep vein thrombosis (DVT), pulmonary embolism (PE), atrial fibrillation & heart attack, and others. In terms of distribution channel, the market has been divided into hospital pharmacies, retail pharmacies, and online pharmacies.

Geographically, the global anticoagulants market has been segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The regions have been divided into major countries/sub-regions. A global overview has been provided, and North America has been analyzed in depth at country as well as product, Indication, and end-user segment levels. North America includes the U.S. and Canada. Europe, Asia Pacific, Latin America, and Middle East & Africa have been briefly profiled at country level. Countries/sub-regions in these regions include the U.K., Germany, France, Italy, Spain, China, Japan, Australia & New Zealand, Brazil, Mexico, GCC Countries, and South Africa. The competition matrix section included in the report is likely to assist existing players to increase market shares and new companies to establish presence in the global anticoagulants market. The report also profiles major players in the global market based on various attributes such as company overview, financial overview, SWOT analysis, key business strategies, product portfolio, and recent developments.

Key players operating in the global anticoagulants market include Bayer Healthcare, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Daiichi Sankyo Company, Limited, Johnson & Johnson Services, Inc., and Sanofi.

The global anticoagulants market has been segmented as follows:

Global Anticoagulants Market, by Route of Administration

Oral
Injectables
Global Anticoagulants Market, by Drug Class

Factor XA Inhibitors (NOAC/DOAC)
Heparins
Direct Thrombin Inhibitors
Vitamin K Antagonists
Global Anticoagulants Market, by Indication

Deep Vein Thrombosis (DVT)
Pulmonary Embolism (PE)
Atrial Fibrillation & Heart Attack
Others
Global Anticoagulants Market, by Distribution channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Anticoagulants Market, by Region

North America
U.S.
Canada
Europe
U.K.
Germany
France
Italy
Spain
Rest of Europe
Asia Pacific
China
Japan
India
Australia & New Zealand
Rest of Asia Pacific
Latin America
Brazil
Mexico
Rest of Latin America
Middle East & Africa
GCC Countries
South Africa
Rest of Middle East & Africa

【レポートの目次】

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Anticoagulants Market

4. Market Overview
4.1. Introduction
4.1.1. Route of Administration Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.3.4. Market Trends
4.4. Global Anticoagulants market analysis and Forecast, 2016–2026
4.5. Porter’s Five Force Analysis

5. Market Outlook
5.1. Key Mergers & Acquisitions

6. Global Anticoagulants Market Analysis and Forecast, by Route of Administration
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Route of Administration, 2016–2026
6.3.1. Oral
6.3.2. Injectable
6.4. Market Attractiveness, by Route of Administration

7. Global Anticoagulants Market Analysis and Forecast, by Drug Class
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Drug Class, 2016–2026
7.3.1. Factor XA Inhibitors (NOAC/DOAC)
7.3.2. Heparins
7.3.3. Direct Thrombin Inhibitors
7.3.4. Vitamin K Antagonists
7.4. Market Attractiveness, by Drug Class

8. Global Anticoagulants Market Analysis and Forecast, by Indication
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Distribution Channel, 2016–2026
8.3.1. Deep Vein Thrombosis
8.3.2. Pulmonary Embolism
8.3.3. Atrial Fibrillation & Heart Attack
8.3.4. Others
8.4. Market Attractiveness, by Distribution Channel

9. Global Anticoagulants Market Analysis and Forecast, by Distribution Channel
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast, by Distribution Channel, 2016–2026
9.3.1. Hospital Pharmacies
9.3.2. Retail Pharmacies
9.3.3. Online Pharmacies
9.4. Market Attractiveness, by Distribution Channel

10. Global Anticoagulants Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Market Value Forecast, by Region
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness, by Region

11. North America Anticoagulants Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Route of Administration, 2016–2026
11.2.1. Oral
11.2.2. Injectables
11.3. Market Value Forecast, by Drug Class, 2016–2026
11.3.1. Factor XA Inhibitors (NOAC/DOAC)
11.3.2. Heparins
11.3.3. Direct Thrombin Inhibitors
11.3.4. Vitamin K Antagonists
11.4. Market Value Forecast, by Distribution Channel, 2016–2026
11.4.1. Deep Vein Thrombosis
11.4.2. Pulmonary Embolism
11.4.3. Atrial Fibrillation & Heart Attack
11.4.4. Others
11.5. Market Value Forecast, by Distribution Channel, 2016–2026
11.5.1. Hospital Pharmacies
11.5.2. Retail Pharmacies
11.5.3. Online Pharmacies
11.6. Market Value Forecast, by Country, 2016–2026
11.6.1. U.S.
11.6.2. Canada
11.7. Market Attractiveness Analysis
11.7.1. By Route of Administration
11.7.2. By Drug Class
11.7.3. By Indication
11.7.4. By Distribution Channel
11.7.5. By Country

12. Europe Anticoagulants Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Route of Administration, 2016–2026
12.2.1. Oral
12.2.2. Injectables
12.3. Market Value Forecast, by Drug Class, 2016–2026
12.3.1. Factor XA Inhibitors (NOAC/DOAC)
12.3.2. Heparins
12.3.3. Direct Thrombin Inhibitors
12.3.4. Vitamin K Antagonists
12.4. Market Value Forecast, by Distribution Channel, 2016–2026
12.4.1. Deep Vein Thrombosis
12.4.2. Pulmonary Embolism
12.4.3. Atrial Fibrillation & Heart Attack
12.4.4. Others
12.5. Market Value Forecast, by Distribution Channel, 2016–2026
12.5.1. Hospital Pharmacies
12.5.2. Retail Pharmacies
12.5.3. Online Pharmacies
12.6. Market Value Forecast, by Country/Sub-region, 2016–2026
12.6.1. Germany
12.6.2. U.K.
12.6.3. France
12.6.4. Italy
12.6.5. Spain
12.6.6. Rest of Europe
12.7. Market Attractiveness Analysis
12.7.1. By Route of Administration
12.7.2. By Drug Class
12.7.3. By Indication
12.7.4. By Distribution Channel
12.7.5. By Country/Sub-Region

13. Asia Pacific Anticoagulants Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Route of Administration, 2016–2026
13.2.1. Oral
13.2.2. Injectables
13.3. Market Value Forecast, by Drug Class, 2016–2026
13.3.1. Factor XA Inhibitors (NOAC/DOAC)
13.3.2. Heparins
13.3.3. Direct Thrombin Inhibitors
13.3.4. Vitamin K Antagonists
13.4. Market Value Forecast, by Distribution Channel, 2016–2026
13.4.1. Deep Vein Thrombosis
13.4.2. Pulmonary Embolism
13.4.3. Atrial Fibrillation & Heart Attack
13.4.4. Others
13.5. Market Value Forecast, by Distribution Channel, 2016–2026
13.5.1. Hospital Pharmacies
13.5.2. Retail Pharmacies
13.5.3. Online Pharmacies
13.6. Market Value Forecast, by Country/Sub-region, 2016–2026
13.6.1. Japan
13.6.2. China
13.6.3. India
13.6.4. Australia & New Zealand
13.6.5. Rest of Asia Pacific
13.7. Market Attractiveness Analysis
13.7.1. By Route of Administration
13.7.2. By Drug Class
13.7.3. By Indication
13.7.4. By Distribution Channel
13.7.5. By Country/Sub-Region

14. Latin America Anticoagulants Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Route of Administration, 2016–2026
14.2.1. Oral
14.2.2. Injectables
14.3. Market Value Forecast, by Drug Class, 2016–2026
14.3.1. Factor XA Inhibitors (NOAC/DOAC)
14.3.2. Heparins
14.3.3. Direct Thrombin Inhibitors
14.3.4. Vitamin K Antagonists
14.4. Market Value Forecast, by Distribution Channel, 2016–2026
14.4.1. Deep Vein Thrombosis
14.4.2. Pulmonary Embolism
14.4.3. Atrial Fibrillation & Heart Attack
14.4.4. Others
14.5. Market Value Forecast, by Distribution Channel, 2016–2026
14.5.1. Hospital Pharmacies
14.5.2. Retail Pharmacies
14.5.3. Online Pharmacies
14.6. Market Value Forecast, by Country/Sub-region, 2016–2026
14.6.1. Brazil
14.6.2. Mexico
14.6.3. Rest of Latin America
14.7. Market Attractiveness Analysis
14.7.1. By Route of Administration
14.7.2. By Drug Class
14.7.3. By Indication
14.7.4. By Distribution Channel
14.7.5. By Country/Sub-Region

15. Middle East & Africa Anticoagulants Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Route of Administration, 2016–2026
15.2.1. Oral
15.2.2. Injectables
15.3. Market Value Forecast, by Drug Class, 2016–2026
15.3.1. Factor XA Inhibitors (NOAC/DOAC)
15.3.2. Heparins
15.3.3. Direct Thrombin Inhibitors
15.3.4. Vitamin K Antagonists
15.4. Market Value Forecast, by Distribution Channel, 2016–2026
15.4.1. Deep Vein Thrombosis
15.4.2. Pulmonary Embolism
15.4.3. Atrial Fibrillation & Heart Attack
15.4.4. Others
15.5. Market Value Forecast, by Distribution Channel, 2016–2026
15.5.1. Hospital Pharmacies
15.5.2. Retail Pharmacies
15.5.3. Online Pharmacies
15.6. Market Value Forecast, by Country/Sub-region, 2016–2026
15.6.1. GCC Countries
15.6.2. Israel
15.6.3. South Africa
15.6.4. Rest of Middle East & Africa
15.7. Market Attractiveness Analysis
15.7.1. By Route of Administration
15.7.2. By Drug Class
15.7.3. By Distribution Channel
15.7.4. By Indication
15.7.5. By Country/Sub-Region

16. Competition Landscape
16.1. Market Player – Competition Matrix
16.2. Market Share Analysis, by Company (2017)
16.3. Company Profiles
16.4 Bayer AG
16.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.4.2. Financial Overview
16.4.3. Product Portfolio
16.4.4. SWOT Analysis
16.4.5. Strategic Overview
16.5. Boehringer Ingelheim International GmbH
16.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.5.2. Financial Overview
16.5.3. Product Portfolio
16.5.4. SWOT Analysis
16.5.5. Strategic Overview
16.6. Bristol-Myers Squibb Company
16.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.6.2. Financial Overview
16.6.3. Product Portfolio
16.6.4. SWOT Analysis
16.6.5. Strategic Overview
16.7. Daiichi Sankyo Company, Limited
16.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.7.2. Financial Overview
16.7.3. Product Portfolio
16.7.4. SWOT Analysis
16.7.5. Strategic Overview
16.8. Sanofi
16.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.8.2. Financial Overview
16.8.3. Product Portfolio
16.8.4. SWOT Analysis
16.8.5. Strategic Overview
16.9. Johnson & Johnson Services
16.9.1. Company Overview (HQ, Business Segments, Employee Strength)
16.9.2. Financial Overview
16.9.3. Product Portfolio
16.9.4. SWOT Analysis
16.9.5. Strategic Overview

List of Tables

Table 01: Global Anticoagulants Market Value (US$ Mn) Forecast, by Route of Administration, 2016–2026
Table 02: Global Anticoagulants Market Value (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 03: Global Anticoagulants Market Value (US$ Mn) Forecast, by Indication, 2016–2026
Table 04: Global Anticoagulants Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 05: Global Anticoagulants Market Size (US$ Mn) and Volume (Units) Forecast, by Region, 2018–2026
Table 06: North America Anticoagulants Market Value (US$ Mn) Forecast, by Country, 2016–2026
Table 07: North America Anticoagulants Market Value (US$ Mn) Forecast, by Route of Administration, 2016–2026
Table 08: North America Anticoagulants Market Value (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 09: North America Anticoagulants Market Value (US$ Mn) Forecast, by Indication, 2016–2026
Table 10: North America Anticoagulants Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 11: Europe Anticoagulants Size Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 12: Europe Anticoagulants Market Value (US$ Mn) Forecast, by Route of Administration, 2016–2026
Table 13: Europe Anticoagulants Market Value (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 14: Europe Anticoagulants Market Value (US$ Mn) Forecast, by Indication, 2016–2026
Table 15: Europe Anticoagulants Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 16: Asia Pacific Anticoagulants Size Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 17: Asia Pacific Anticoagulants Market Value (US$ Mn) Forecast, by Route of Administration, 2016–2026
Table 18: Asia Pacific Anticoagulants Market Value (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 19: Asia Pacific Anticoagulants Market Value (US$ Mn) Forecast, by Indication, 2016–2026
Table 20: Asia Pacific Anticoagulants Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 21: Latin America Anticoagulants Size Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 22: Latin America Anticoagulants Market Value (US$ Mn) Forecast, by Route of Administration, 2016–2026
Table 23: Latin America Anticoagulants Market Value (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 24: Latin America Anticoagulants Market Value (US$ Mn) Forecast, by Indication, 2016–2026
Table 25: Latin America Anticoagulants Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 26: Middle East & Africa Anticoagulants Size Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 27: Middle East & Africa Anticoagulants Market Value (US$ Mn) Forecast, by Route of Administration, 2016–2026
Table 28: Middle East & Africa Anticoagulants Market Value (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 29: Middle East & Africa Anticoagulants Market Value (US$ Mn) Forecast, by Indication, 2016–2026
Table 30: Middle East & Africa Anticoagulants Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026

List of Figures

Figure 01: Global Anticoagulants Market Size Value (US$ Mn) Forecast, 2016–2026
Figure 02: Global Anticoagulants Market Value Share (%), by Route of Administration, 2018
Figure 03: Global Anticoagulants Market Value Share (%), by Drug Class, 2018
Figure 04: Global Anticoagulants Market Value Share (%), by End-user, 2018
Figure 05: Global Anticoagulants Market Value Share (%), by Region, 2018
Figure 06: Global Anticoagulants Market Value Share, by Route of Administration, 2018 and 2026
Figure 07: Global Anticoagulants Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Oral, 2016–2026
Figure 08: Global Anticoagulants Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Injectables, 2016–2026
Figure 09: Global Anticoagulants Market Attractiveness, by Route of Administration, 2018–2026
Figure 10: Global Anticoagulants Market Value Share, by Drug Class, 2018 and 2026
Figure 11: Global Anticoagulants Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Factor XA Inhibitors, 2016–2026
Figure 12: Global Anticoagulants Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Heparins, 2016–2026
Figure 13: Global Anticoagulants Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Direct Thrombin Inhibitors, 2016–2026
Figure 14: Global Anticoagulants Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Vitamin K Antagonists, 2016–2026
Figure 15: Global Anticoagulants Market Attractiveness, by Drug Class, 2018–2026
Figure 16: Global Anticoagulants Market Value Share, by Indication, 2018 and 2026
Figure 17: Global Anticoagulants Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Deep Vein Thrombosis (DVT), 2016–2026
Figure 18: Global Anticoagulants Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Pulmonary Embolism (PE), 2016–2026
Figure 19: Global Anticoagulants Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Atrial Fibrillation & Heart Attack, 2016–2026
Figure 20: Global Anticoagulants Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Others, 2016–2026
Figure 21: Global Anticoagulants Market Attractiveness, by Indication, 2018–2026
Figure 22: Global Anticoagulants Market Value Share, by Distribution Channel, 2018 and 2026
Figure 23: Global Anticoagulants Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Hospitals Pharmacies, 2016–2026
Figure 24: Global Anticoagulants Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Retail Pharmacies, 2016–2026
Figure 25: Global Anticoagulants Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Online Pharmacies, 2016–2026
Figure 26: Global Anticoagulants Market Attractiveness, by Distribution Channel, 2018–2026
Figure 27: Global Anticoagulants Market Value Share Analysis, by Region, 2018 and 2026
Figure 28: Global Anticoagulants Market Attractiveness Analysis, by Region, 2018 and 2026
Figure 29: North America Anticoagulants Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2016–2026
Figure 30: North America Anticoagulants Market Value Share, by Country, 2018 and 2026
Figure 31: North America Anticoagulants Market Attractiveness, by Country, 2018–2026
Figure 32: North America Anticoagulants Market Value Share, by Route of Administration, 2018 and 2026
Figure 33: North America Anticoagulants Market Attractiveness, by Route of Administration, 2018–2026
Figure 34: North America Anticoagulants Market Value Share, by Drug Class, 2018 and 2026
Figure 35: North America Anticoagulants Market Attractiveness, by Drug Class, 2018–2026
Figure 36: North America Anticoagulants Market Value Share, by Indication, 2018 and 2026
Figure 37: North America Anticoagulants Market Attractiveness, by Indication, 2018–2026
Figure 38: North America Anticoagulants Market Value Share, by Distribution Channel, 2018 and 2026
Figure 39: North America Anticoagulants Market Attractiveness, by Distribution Channel, 2018–2026
Figure 40: Europe Anticoagulants Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2016–2026
Figure 41: Europe Anticoagulants Market Value Share, by Country/Sub-region, 2018 and 2026
Figure 42: Europe Anticoagulants Market Attractiveness, by Country/Sub-region, 2018–2026
Figure 43: Europe Anticoagulants Market Value Share, by Route of Administration, 2018 and 2026
Figure 44: Europe Anticoagulants Market Attractiveness, by Route of Administration, 2018–2026
Figure 45: Europe Anticoagulants Market Value Share, by Drug Class, 2018 and 2026
Figure 46: Europe Anticoagulants Market Attractiveness, by Drug Class, 2018–2026
Figure 47: Europe Anticoagulants Market Value Share, by Indication, 2018 and 2026
Figure 48: Europe Anticoagulants Market Attractiveness, by Indication, 2018–2026
Figure 49: Europe Anticoagulants Market Value Share, by Distribution Channel, 2018 and 2026
Figure 50: Europe Anticoagulants Market Attractiveness, by Distribution Channel, 2018–2026
Figure 51: Asia Pacific Anticoagulants Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2016–2026
Figure 52: Asia Pacific Anticoagulants Market Value Share, by Country/Sub-region, 2018 and 2026
Figure 53: Asia Pacific Anticoagulants Market Attractiveness, by Country/Sub-region, 2018–2026
Figure 54: Asia Pacific Anticoagulants Market Value Share, by Route of Administration, 2018 and 2026
Figure 55: Asia Pacific Anticoagulants Market Attractiveness, by Route of Administration, 2018–2026
Figure 56: Asia Pacific Anticoagulants Market Value Share, by Drug Class, 2018 and 2026
Figure 57: Asia Pacific Anticoagulants Market Attractiveness, by Drug Class, 2018–2026
Figure 58: Asia Pacific Anticoagulants Market Value Share, by Indication, 2018 and 2026
Figure 59: Asia Pacific Anticoagulants Market Attractiveness, by Indication, 2018–2026
Figure 60: Asia Pacific Anticoagulants Market Value Share, by Distribution Channel, 2018 and 2026
Figure 61: Asia Pacific Anticoagulants Market Attractiveness, by Distribution Channel, 2018–2026
Figure 62: Latin America Anticoagulants Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2016–2026
Figure 63: Latin America Anticoagulants Market Value Share, by Country/Sub-region, 2018 and 2026
Figure 64: Latin America Anticoagulants Market Attractiveness, by Country/Sub-region, 2018–2026
Figure 65: Latin America Anticoagulants Market Value Share, by Route of Administration, 2018 and 2026
Figure 66: Latin America Anticoagulants Market Attractiveness, by Route of Administration, 2018–2026
Figure 67: Latin America Anticoagulants Market Value Share, by Drug Class, 2018 and 2026
Figure 68: Latin America Anticoagulants Market Attractiveness, by Drug Class, 2018–2026
Figure 69: Latin America Anticoagulants Market Value Share, by Indication, 2018 and 2026
Figure 70: Latin America Anticoagulants Market Attractiveness, by Indication, 2018–2026
Figure 71: Latin America Anticoagulants Market Value Share, by Distribution Channel, 2018 and 2026
Figure 72: Latin America Anticoagulants Market Attractiveness, by Distribution Channel, 2018–2026
Figure 73: Middle East & Africa Anticoagulants Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2016–2026
Figure 74: Middle East & Africa Anticoagulants Market Value Share, by Country/Sub-region, 2018 and 2026
Figure 75: Middle East & Africa Anticoagulants Market Attractiveness, by Country/Sub-region, 2018–2026
Figure 76: Middle East & Africa Anticoagulants Market Value Share, by Route of Administration, 2018 and 2026
Figure 77: Middle East & Africa Anticoagulants Market Attractiveness, by Route of Administration, 2018–2026
Figure 78: Middle East & Africa Anticoagulants Market Value Share, by Drug Class, 2018 and 2026
Figure 79: Middle East & Africa Anticoagulants Market Attractiveness, by Drug Class, 2018–2026
Figure 80: Middle East & Africa Anticoagulants Market Value Share, by Indication, 2018 and 2026
Figure 81: Middle East & Africa Anticoagulants Market Attractiveness, by Indication, 2018–2026
Figure 82: Middle East & Africa Anticoagulants Market Value Share, by Distribution Channel, 2018 and 2026
Figure 83: Middle East & Africa Anticoagulants Market Attractiveness, by Distribution Channel, 2018–2026

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[抗凝固薬の世界市場]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆